Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently completed kilogram-scale manufacturing of a key precursor for ONC010's active pharmaceutical ingredient, a critical step toward formulation development, GMP production, and clinical studies.
To support these efforts, Onco-Innovations signed a letter of intent with Nanosoft Polymers to collaborate on polymer development, drug delivery optimization, and formulation work. Additionally, engagements with Nucro-Technics and Avance Clinical are facilitating bioanalytical development and clinical and regulatory planning. These initiatives reflect the company's broader strategy to build the manufacturing, formulation, and clinical infrastructure necessary to advance ONC010 toward future first-in-human studies.
ONC010 targets PNKP, an enzyme involved in DNA repair, to overcome treatment resistance in solid tumors. By inhibiting PNKP, the drug aims to enhance the effectiveness of existing therapies and improve patient outcomes. The exclusive worldwide license to this patented technology positions Onco-Innovations to address significant unmet needs in oncology.
“These milestones are vital as we prepare for clinical development,” said a company representative. The progress in manufacturing and partnerships underscores Onco-Innovations’ commitment to bringing innovative cancer treatments to patients. For more information, visit the company’s website at https://oncoinnovations.com/.
The latest news and updates regarding ONNVF are available in the company’s newsroom at https://ibn.fm/ONNVF. This announcement highlights the importance of continued investment in oncology research and the potential of novel therapies like ONC010 to transform cancer treatment.
